

# Lipid-Lowering Therapies: Risks in Women and Evidence-Based Options

Tina Shah, MD, FACC  
Salim S. Virani, MD, PhD

## ★ CME Credit

Presented at the 8th Annual Women's Heart & Vascular Symposium, Texas Heart Institute; Houston, 20 January 2018.

**Section Editor:**  
Stephanie A. Coulter, MD

**Key words:**  
Anticholesteremic agents/therapeutic use; cardiovascular diseases/drug therapy/prevention & control; cholesterol, LDL/blood; diabetes mellitus, type 2/chemically induced; drug therapy, combination; female; hydroxymethylglutaryl-CoA reductase inhibitors/therapeutic use; randomized controlled trials as topic; sex factors; treatment outcome

**From:** Section of Cardiology, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, Texas 77030

**Address for reprints:**  
Tina Shah, MD,  
Section of Cardiology,  
MEDVAMC (111-B),  
2002 Holcombe Blvd.,  
Houston, TX 77030

**E-mail:** tina.shah@bcm.edu

© 2018 by the Texas Heart®  
Institute, Houston

**C**ardiovascular disease is the chief cause of death in women in the United States. Therefore, sex-based (biological) and gender-based (sociocultural) variations in the pathophysiology, symptoms, and response to pharmacologic interventions should be considered between men and women during primary and secondary prevention of coronary artery disease. In the evaluation of patients who have signs and symptoms of myocardial ischemia, women typically exhibit more symptoms and functional disability than do men. They also have a higher prevalence of nonobstructive coronary artery disease<sup>1</sup> and worse cardiovascular outcomes. Therefore, it is important to recognize the prevalence of traditional atherosclerotic cardiovascular disease (ASCVD) risk factors (dyslipidemia, hypertension, smoking, obesity, physical inactivity, and diabetes mellitus [DM]), their differential impact, and emerging, nontraditional risk factors unique to or more often identified in women (such as pregnancy-related disorders, psychological depression, and autoimmune diseases).

## Statin Use in Women

Abnormally low levels of high-density-lipoprotein cholesterol and elevated low-density-lipoprotein cholesterol (LDL-C) are well established as modifiable risk factors for cardiovascular disease. Greater ASCVD risk is typically not observed in women before menopause. As in men, pharmacologic therapy for hyperlipidemia in women as secondary prevention has clearly reduced recurrent cardiovascular events and ASCVD mortality rates. However, data on the benefits of primary prevention in women are lacking; most primary prevention trials included few women and provided no sex-specific results. Statins are the cornerstone of LDL-C-lowering therapy and ASCVD prevention. Investigators who performed a meta-analysis of 27 statin therapy trials concluded that the proportional reduction in major vascular events per 1.0 mmol/L reduction in LDL-C was similar for men and women—risk ratio for women, 0.84 (99% CI, 0.78–0.91); versus men, 0.78 (99% CI, 0.75–0.81)—regardless of the baseline level of ASCVD risk or subtype of ASCVD outcome.<sup>2</sup> Despite the known benefits of lipid-lowering medications, investigators<sup>3</sup> have identified sex-specific differences in consistent treatment and adherence to lipid-lowering regimens: women are less likely to be prescribed statin therapy and adhere less to it. These concerns underscore the importance of improving the awareness of patients and clinicians about the benefits of lipid-lowering therapies, and further analyzing reasons for the disparities.

## Side Effects of Statins in Women

No compelling evidence supports the claim that statins are less safe for women than for men. In the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study, which enrolled more women than had any other statin trial, rates of myopathy between men and women did not differ.<sup>4</sup> The results, however, revealed that women taking rosuvastatin had a greater increase in HbA<sub>1c</sub> level and more risk of developing new DM than did women who took a placebo. The precise mechanism behind statin-induced DM remains unclear, although most patients who develop DM have prediabetes or baseline features of metabolic syndrome that indicate a high risk of DM. It is hypothesized that statins have detrimental effects on insulin sensitivity and  $\beta$ -cell secretion. Various statins and various doses of statins also appear to have differential metabolic effects that need

to be considered when developing treatment plans for patients at high risk for DM.

New-onset DM consequent to statin therapy has not yet been associated with an increase in adverse cardiovascular events. In addition, data suggest that the clinical benefits of statin therapy outweigh the increased risk of DM. Investigators<sup>5</sup> who performed a meta-analysis estimated that treating 255 patients with standard-dose statin therapy for 4 years would avoid 9 vascular events and lead to one case of new-onset DM (9:1 benefit-risk ratio). Despite few long-term studies, the benefits of statins outweigh the risks in women, as well. It is therefore recommended that statins be first-line therapy for male and female patients at risk of ASCVD. Patients taking statins and who are at high risk for DM should undergo regular blood glucose monitoring. It is also recommended that these patients be counseled about regular physical activity and dietary interventions that would reduce their risk of developing DM.

### Nonstatin Therapies

Nonstatin therapies like ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors may also reduce the risk of ASCVD. Results of the IMPROVE-IT trial showed the benefit of adding ezetimibe to statins among men and women with recent acute coronary syndrome, thus supporting the use of intensive lipid-lowering therapy in combination to optimize cardiovascular outcomes.<sup>6</sup> In the FOURIER trial, adding evolocumab to high-intensity statin therapy in patients with stable ASCVD reduced the risk of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, and coronary revascularization when compared with placebo; the benefits were largely consistent across major subgroups, including age, sex, and type of atherosclerotic vascular disease.<sup>7</sup>

### Conclusion

The substantial differences in epidemiology, pathology, and therapeutic response between men and women

should be considered when treating women who have or might have ischemic heart disease. For evaluation of sex-related differences in the efficacy of statins prescribed to manage ASCVD, women need to be better represented in prospective randomized clinical trials.

## References

1. Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) study: part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. *J Am Coll Cardiol* 2006;47(3 Suppl):S4-S20.
2. Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. *Lancet* 2015;385(9976):1397-405.
3. Virani SS, Woodard LD, Ramsey DJ, Urech TH, Akeroyd JM, Shah T, et al. Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. *Am J Cardiol* 2015;115(1):21-6.
4. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. *Circulation* 2010;121(9):1069-77.
5. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet* 2010;375(9716):735-42.
6. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med* 2015;372(25):2387-97.
7. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med* 2017;376(18):1713-22.